Drug Approval | July 05, 2023
Zydus receives final approval from the USFDA for Oxcarbazepine Tablets
The product will be manufactured at the group's formulation manufacturing facility in Baddi, Himachal Pradesh (India)
The product will be manufactured at the group's formulation manufacturing facility in Baddi, Himachal Pradesh (India)
Takes over the commercialization of Biosimilars Business from Viatris in 70+ countries
The detailed terms in relation to the Rights Issue, including but not limited to the issue price, rights entitlement ratio, record date, timing and terms of payment will be determined in due course.
Cyanocobalamin Nasal Spray (RLD Nascobal) had estimated annual sales of USD 69 million in the U.S. (IQVIA MAT Mar 2023)
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x
SHL Medical announces the acquisition of LCA Automation AG, a Swiss innovative automation solutions provider
The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023
Alembic has a cumulative total of 184 ANDA approvals (159 final approvals and 25 tentative approvals) from USFDA.
The zero-observation outcome reflects the company's robust quality management systems and commitment to excellence in its operations.
Intent to start at least 5 innovative Phase 3 vaccine programs by 2025
Subscribe To Our Newsletter & Stay Updated
